Results 1 to 10 of about 13,106 (183)

Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study [PDF]

Medical Sciences
Background: Higher-risk myelodysplastic neoplasms (HR-MDS) are associated with poor survival and a substantial risk of leukemic transformation. Although azacitidine is a standard treatment in this setting, comparative real-world data remain limited.
Mihai-Emilian Lapadat, Oana Stanca, Irina Nicoleta Triantafyllidis, Anca Mariana Ciobanu, Nicoleta Mariana Berbec, Cristina Negotei, Cristian Tudor Barta, Ana Maria Bordea, Madalina Marilena Oprea, Andrei Colita   +9 more
doaj   +2 more sources

Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome [PDF]

Frontiers in Oncology
Response rates in platinum-resistant ovarian cancer remain low (16–30%) and decline with subsequent lines of therapy. Mirvetuximab soravtansine (MIRV), an antibody–drug conjugate targeting folate receptor alpha (FRα), has demonstrated clinically ...
Sophonie Shilonite Njonou Noujiep, Judith Altmann, Lars Bullinger, Lars Bullinger, Lars Bullinger, Jalid Sehouli, Jalid Sehouli, Jalid Sehouli   +7 more
doaj   +2 more sources

Safety and efficacy of azacitidine in myelodysplastic syndromes

Drug Design, Development and Therapy, 2010
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are ...
Guillermo Garcia-Manero, CARLOS E Vigil
exaly   +2 more sources

Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition [PDF]

BMC Cancer
Background We aimed to characterise the molecular effects of treating myelodysplastic syndrome (MDS) cells with the DNA methyltransferase inhibitor azacitidine and an PIM-2 inhibitor, focusing on their potential synergistic effects.
Yixuan Guo, Zhaoyun Liu, Wenhui Lei, Xiaohan Liu, Chun Yang, Kai Ding, Rong Fu   +6 more
doaj   +2 more sources

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

Haematologica, 2023
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary.
Jonathan A. Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T. Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O’Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Katie Zhou, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea   +22 more
doaj   +1 more source

Theoretical investigation of fullerene nano carrier anti-cancer drug delivery of Azacitidine [PDF]

Nanochemistry Research, 2023
Azacitidine, known under the brand Vidaza, has therapeutic applications for several health complications, including myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia.
Niloofar Jafari, Sayed Ali Ahmadi, Razieh Razavi   +2 more
doaj   +1 more source

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens

Haematologica, 2022
Time at home is a critically important outcome to adults with acute myeloid leukemia (AML) when selecting treatment; however, no study to date has adequately described the amount of time older adults spend at home following initiation of chemotherapy ...
Christopher E. Jensen, Hilary M. Heiling, Konan E. Beke, Allison M. Deal, Ashley L. Bryant, Lorinda A. Coombs, Matthew C. Foster, Daniel R. Richardson   +7 more
doaj   +1 more source

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Journal of Hematology & Oncology, 2021
Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal.
Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C. L. Beach, Herve Dombret   +21 more
doaj   +1 more source

Physicochemical stability of azacitidine suspensions at 25 mg/mL in polypropylene syringes stored under different conditions of storage

Pharmaceutical Technology in Hospital Pharmacy, 2022
Azacitidine is a pyrimidine nucleoside analogue whose stability is temperature dependent. Numerous publications have studied the stability of this drug with discordant results. The purpose of this work is to study the stability of azacitidine suspensions
Trambloy Quentin, Vigneron Jean, Clarot Igor, Blaise Franck, D’Huart Elise, Demoré Béatrice   +5 more
doaj   +1 more source

The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma

Haematologica, 2008
Background Azacitidine is a DNA methyltransferase inhibitor and cytotoxic agent known to induce apoptosis of some cancer cells. This study evaluated the pre-clinical potential of azacitidine as a therapeutic agent for multiple myeloma.Design and Methods ...
Tiffany Khong, Janelle Sharkey, Andrew Spencer   +2 more
doaj   +1 more source